MRC Technology announced it has entered into collaboration with Renishaw Diagnostics Ltd (RDL), developer of the RenDx® multiplex assay system, to identify and design novel clinical diagnostic tests for infectious disease.
The agreement will benefit from the combination of RDL’s proprietary multiplex screening technology and expertise in assay development, with MRC Technology’s experience in developing early stage research for clinical application and commercialisation. The focus of the collaboration is to identify and accelerate research which has potential in infectious disease diagnostics.
Rupert Jones, RDL’s General Manager commented, “RDL is delighted to be working with MRC Technology as a leader in translating basic research into commercial opportunities. MRC Technology's expertise and experience will allow us to accelerate development of our assay portfolio, enhancing the capabilities of the RenDx platform and providing end users with additional value and flexibility.”
The RenDx multiplex assay system is based on surface enhanced resonance Raman scattering, providing automated, multiplex, high sensitivity, in vitro screening for clinical research.
“MRC Technology will build a capability in early stage translation of diagnostic opportunities from academia at our laboratory facilities in Edinburgh,” added Mike Dalrymple, MRC Technology. “We are delighted to be working with RDL to identify opportunities that will take advantage of RDL’s platform and capabilities. Key to success will be ensuring information exchange between RDL and MRC Technology scientists, thus opening up the potential for future research collaboration.”